In this study, we aimed to examine different PCa cell lines to assess the phenotypic response of PCa cells in response to R1881 and enzalutamide treatment using PSA as a biomarker and assess the differences in the metastatic disease states. The gene discussed is KLK3; the disease is metastatic neoplasm.